Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Oncol. 2011 Oct;18 Suppl 2:S11-9.

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.

Author information

1
Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, ON.

Abstract

Traditionally, overall survival (os) has been considered the "gold standard" for evaluating new systemic oncologic therapies, because death is easy to define, is easily compared across disease sites, and is not subject to investigator bias. However, as the available options for continuing therapy increase, the use of os as a clinical trial endpoint has become problematic because of the increasing crossover and contamination of trials. As a result, the approval of promising new therapies may be delayed.Many clinicians believe that progression-free survival (pfs) is a more viable option for evaluating new therapies in metastatic and advanced renal cell carcinoma. As with all endpoints, pfs has inherent biases, and those biases must be addressed to ensure that trial results are not compromised and that they will be accepted by regulatory authorities. In this paper, we examine the issues surrounding the use of pfs as a clinical trial endpoint, and we suggest solutions to ensure that data integrity is maintained.

KEYWORDS:

Kidney cancer; clinical trial endpoints; overall survival; progression-free survival; regulatory approval

PMID:
21969807
PMCID:
PMC3176905
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multimed Inc. Icon for PubMed Central
    Loading ...
    Support Center